Incremental cost effectiveness of pneumococcal vaccination in Kenya and sensitivity analysis of the impact of indirect effects for PCV10 and PCV13.
Domain:
healthcareRecord type:
paper
Creator:
PhiUllMosJen
Host:
*
All costs, pneumococcal episodes and deaths are discounted at an annual rate of 3%.
Similar
Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in KenyaPneumococcal conjugate vaccination in The Gambia: health impact, cost effectiveness and budget implicationsA health benefit and cost-effectiveness analysis of pneumococcal conjugate vaccination program in NigeriaThe merits of sustaining pneumococcal vaccination after transitioning from Gavi support – a modelling and cost-effectiveness study for KenyaThe impact of introduction of the 10-valent pneumococcal conjugate vaccine (PCV10) on pneumococcal carriage in NigeriaImpact and Cost-Effectiveness of Human Papillomavirus Vaccination Campaigns